Pembrolizumab, Vibostolimab — Drug Intelligence | 13 EU Trials

Filter these 13 trials by condition, phase, country and more.

Open in Search →

13 Registered trials

2 Recruiting

9 Completed trials

1 Sponsors

20 Countries

Phase III

Phase II

Phase I/II

Phase III: 5 Phase II/III: 1 Phase II: 3 Phase I/II: 3 Phase III/IV: 1

Oversight events:

1 serious breach 4 urgent safety measures 1 corrective measure across 6 trials

View oversight register →

Indications tested

Non-small cell lung cancer metastatic 2 Colorectal cancer stage IV 1 Renal cell carcinoma 1

Sponsors using this IMP

Merck Sharp & Dohme LLC 13

All trials

13 total

Clinical trial of MK-7648A in adults and children with skin cancer Not authorised

2022-501417-31-00 Phase III 9 countries Merck Sharp & Dohme LLC
LIGHTBEAM-U01 Substudy 01B: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Pembrolizumab in Combination with Investigational Ag… Not authorised

2023-507179-23-00 Phase I/II 1 country Merck Sharp & Dohme LLC
A clinical study of different treatments for kidney cancer (MK-3475-03A) Recruiting

2023-506838-68-00 Phase I/II 5 countries Merck Sharp & Dohme LLC
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) Recruiting

2023-506987-15-00 Phase I/II 11 countries Merck Sharp & Dohme LLC
Clinical Trial of MK-7684A with chemotherapy for extensive stage small cell lung cancer (ES-SCLC) Ended

2023-503517-30-00 Phase III 14 countries Merck Sharp & Dohme LLC
A Multi Arm Study in Participants with MSI-High Metastatic Colorectal Cancer Ended

2022-502100-70-00 Phase II/III 13 countries Merck Sharp & Dohme LLC
Clinical trial of MK-7648A in adults and children with skin cancer Ended

2022-501417-31-01 Phase III 9 countries Merck Sharp & Dohme LLC
A study of MK7684A in Combination with radiation and chemotherapy versus radiation and chemotherapy followed by Durvalumab for patients with… Ended

2022-502752-31-00 Phase III/IV 11 countries Merck Sharp & Dohme LLC
Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination with Chemotherapy Versus Pembrolizumab Plus Chemotherapy as Fir… Ended

2023-506074-12-00 Phase III 5 countries Merck Sharp & Dohme LLC
7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors Ended

2023-505284-36-00 Phase II 6 countries Merck Sharp & Dohme LLC
A study of MK7684A versus Pembrolizumab in PD-L1 Positive Metastatic NSCLC (KEYVIBE-003) Ended

2023-505362-28-00 Phase III 2 countries Merck Sharp & Dohme LLC
MK-7684A (new drug co-formulation of pembrolizumab with an anti-TIGIT) plus docetaxel works to help stop or slow down the growth of your non… Ended

2022-501252-28-00 Phase II 9 countries Merck Sharp & Dohme LLC
Pembrolizumab (MK-3475) and pembrolizumab in combination with other investigational agents in high risk NMIBC patients unresponsive to BCG Ended

2022-502526-41-00 Phase II 7 countries Merck Sharp & Dohme LLC

Showing 1–13 of 13 trials

← All drugs A–Z